Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQXP | ISIN: IL0011429839 | Ticker-Symbol: 5DT
Frankfurt
06.06.25 | 08:01
1,714 Euro
-0,12 % -0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENTERA BIO LTD Chart 1 Jahr
5-Tage-Chart
ENTERA BIO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,7921,80606.06.
1,7641,87806.06.

Aktuelle News zur ENTERA BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.05.Entera Bio files $100M mixed securities shelf1
30.05.Entera Bio Ltd. - S-8, Securities to be offered to employees in employee benefit plans1
09.05.Entera Bio GAAP EPS of -$0.06 beats by $0.011
ENTERA BIO Aktie jetzt für 0€ handeln
09.05.Entera Bio Ltd.: Entera Bio Announces First Quarter 2025 Financial Results and Business Updates211JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key...
► Artikel lesen
09.05.Entera Bio Ltd. - 10-Q, Quarterly Report1
09.05.Entera Bio Ltd. - 8-K, Current Report-
09.05.Nagravision-Bango partnership brings over 100 subscription services to OpenTV ENTera5
07.05.Kudelski Group: NAGRAVISION Partners with Bango to Bring Over 100 Subscription Services to OpenTV ENTera, Driving Multi-Service Engagement for Telco Service Providers401Kudelski Group / Key word(s): Miscellaneous NAGRAVISION Partners with Bango to Bring Over 100 Subscription Services to OpenTV ENTera, Driving Multi-Service Engagement for Telco...
► Artikel lesen
15.04.Entera Bio reports positive phase 2 results for osteoporosis treatment14
28.03.Entera Bio GAAP EPS of -$0.25 beats by $0.03, revenue of $0.18M beats by $0.04M1
28.03.Entera Bio Ltd.: Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates575JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and...
► Artikel lesen
28.03.Entera Bio Ltd. - 10-K, Annual Report2
28.03.Entera Bio Ltd. - 8-K, Current Report1
19.03.OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-19
18.03.Opko and Entera focus on oral care for obesity and metabolic disorders3
18.03.OPKO & Entera Bio To Develop First Oral GLP-1/Glucagon Dual Agonist6
17.03.Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic5
17.03.Entera Bio Ltd.: OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders333MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies...
► Artikel lesen
17.03.Entera Bio Ltd. - 8-K, Current Report1
24.02.Entera Bio Ltd.: Entera Bio to Participate in Upcoming Events1
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1